HemaSphere (Jun 2022)

P591: PRELIMINARY RESULTS OF A PHASE I STUDY OF CLIFUTINIB, A HIGHLY SELECTIVE, POTENT ORAL FLT-3 INHIBITOR, IN PATINETS WITH FLT3-MUTATED RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA

  • W. Yu,
  • X. Wei,
  • Z. Ge,
  • Y. Li,
  • Z. Jiang,
  • L. Yang,
  • L. Lin,
  • Y. Yao,
  • X. Deng,
  • X. Du,
  • Y. Li,
  • T. Chen,
  • X. Feng,
  • J. Zhou,
  • M. Hou,
  • R. Fu,
  • J. Lan,
  • X. Hu,
  • S. Huang,
  • J. Wang,
  • X. Du,
  • H. Yang,
  • H. Yang,
  • H. Wang,
  • L. Zheng,
  • Z. Wang,
  • B. Liu,
  • N. Kang,
  • Y. Zhuang,
  • Y. Zhang,
  • J. Jin

DOI
https://doi.org/10.1097/01.HS9.0000845252.68424.50
Journal volume & issue
Vol. 6
pp. 490 – 491

Abstract

Read online

No abstracts available.